Skip to main content
Premium Trial:

Request an Annual Quote

Lion CEO Friederich Von Bohlen To Step Down

NEW YORK, Dec. 15 (GenomeWeb News) - Friedrich von Bohlen, the CEO of Lion Bioscience, has announced his resignation, which will be effective December 31st, the Heidelberg, Germany company said today.


"Dr. von Bohlen and the supervisory board are convinced that Lion is now entering into a new phase of development that requires even stronger IT competence," the company said in a statement issued today. "With this milestone, Dr. von Bohlen proactively allows for new opportunities at Lion."


Von Bohlen, a dynamic and sometimes outspoken personality, founded the company and led it through its IPO in 2000, as well as the signing of major deals with Bayer, Celera, and IBM; the acquisition of NetGenics, and several rounds of restructuring and layoffs this year and last to refocus the company on its IT strengths.


Martin Hollenhorst, Chief Financial Officer, and Daniel Keesman, Chief Business Officer, will lead the company beginning Jan. 1.


The supervisory board has proposed that von Bohlen be elected as an additional member of the board at the next shareholders meeting on Aug. 12th.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.